Silexion Therapeutics Corp (SLXN) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on developing RNA-interference therapeutics for cancers driven by the KRAS oncogene, with a lead candidate (SIL204) for locally advanced pancreatic cancer. The company completed a business combination with Moringa Acquisition Corp in August 2024. As of March 31, 2025, the company had 8,692,392 ordinary shares outstanding.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,735) | $(1,423) |
| Loss Per Share (Basic & Diluted) | $(0.26) | $(12.29) |
| Cash and Cash Equivalents | $6,152 | $2,781 |
| Total Assets | $8,308 | $3,585 |
| Total Liabilities | $5,722 | $6,852 |
| Shareholders' Equity | $2,586 | $(3,989) |
| Operating Cash Flow | $(2,453) | $(1,752) |
Material Changes vs. Prior Period
- Financing Activities: The company raised significant capital in Q1 2025, resulting in a net cash inflow from financing activities of $7.4 million compared to negligible activity in Q1 2024. This included a public offering raising ~$5.0 million and an induced warrant exercise raising ~$3.3 million.
- Operating Expenses: Total operating expenses increased to $1.65 million from $1.25 million.
- Research & Development (R&D): Decreased by 40% to $0.59 million, primarily due to lower subcontractor costs as API development activities shifted to manufacturing.
- General & Administrative (G&A): Increased by 267% to $1.06 million, driven by higher payroll and professional service fees associated with public company compliance and financing activities.
- Liquidity: Cash and cash equivalents increased from $1.2 million at the start of the period to $6.2 million at period end, largely due to the equity financings.
- Debt Settlement: The company settled the EarlyBirdCapital convertible promissory note in March 2025 through a combination of cash payments and the issuance of 277,777 ordinary shares.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Current cash is estimated to fund operations only into the fourth quarter of 2025.
- Capital Requirements: The company expects to continue incurring significant losses and will need to raise substantial additional funding to advance clinical trials for SIL204 and cover operating costs.
- Financing Strategy: Future funding is expected to come from public/private equity offerings, the existing Equity Line of Credit (ELOC) with White Lion Capital (up to $15 million capacity), and strategic alliances. The company has already utilized $3.1 million of the ELOC.
- Risks: Key risks include the inability to raise capital on acceptable terms, dilution to shareholders, the unproven nature of the RNAi platform for oncology, and potential impacts from the ongoing conflict in Israel (though management currently believes operations are not materially impacted).
Investor Verification Checklist
- Cash Runway: Verify the timeline for cash depletion (estimated Q4 2025) against the burn rate and upcoming clinical trial milestones.
- Dilution Impact: Assess the dilution from the recent public offering, induced warrant exercises, and the remaining capacity under the ELOC and Sponsor Promissory Note.
- Debt Obligations: Confirm the status of the $2.99 million Related Party Promissory Note (Sponsor Note) and its conversion terms.
- Grant Obligations: Review the $5.8 million in royalty-bearing grants from the Israeli Innovation Authority and the potential future royalty payments (3-5% of sales).
- Going Concern Status: Monitor subsequent filings for updates on the "substantial doubt" disclosure and any new financing announcements.